Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs →
glpzoom

Retatrutide retatrutide

Weight LossBy Eli Lilly

Investigational triple agonist (GLP-1 / GIP / glucagon). Phase 3 weight loss approached ~24%, the highest yet. Not FDA-approved; expected 2027.

Retatrutide delivery device illustration
Jump to section
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.

What is Retatrutide?

Retatrutide is Eli Lilly's investigational triple hormone-receptor agonist, hitting GLP-1, GIP, and glucagon receptors. It is NOT FDA-approved and not yet for sale. Phase 2 and ongoing Phase 3 (TRIUMPH program) data have shown mean weight loss approaching 24% at the highest dose, the largest of any GLP-1-class agent reported to date. Industry expectation is an FDA decision around 2027. There are no legitimate compounded or telehealth retatrutide products; any seller offering it now is operating outside the law.

How does Retatrutide work?

Where semaglutide hits one receptor and tirzepatide two, retatrutide adds a third: the glucagon receptor. Glucagon-receptor activation increases energy expenditure on top of the appetite-suppression and glycemic effects of GLP-1/GIP, which is the leading hypothesis for its larger weight-loss signal. The trade-off under study is tolerability and heart-rate effects at the highest doses.

Who can take Retatrutide?

Not applicable yet, retatrutide is investigational and available only through clinical trials. When approved, expect obesity and type 2 diabetes indications mirroring the rest of the class, with the same thyroid C-cell contraindication.

How is Retatrutide taken?

Investigational. Trial dosing is once-weekly subcutaneous injection with gradual titration; final approved doses are not set.

How much does Retatrutide cost?

No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product.

What side effects can Retatrutide cause?

Trial adverse events mirror the GLP-1 class (nausea, vomiting, diarrhea, dose-dependent), with attention in studies to heart-rate increase and tolerability at the top dose. Full safety profile pending Phase 3 completion.

What if I miss a dose of Retatrutide?

Not applicable, retatrutide is not commercially dosed. Trial participants follow study protocols.

Related terms

Related topics

How to get it

  1. Take the eligibility quiz

    5 minutes of medical-history questions matched to the medication's FDA criteria. Free, no commitment.

  2. Submit ID + a recent photo

    Required by every legitimate US telehealth platform to verify identity and meet state prescribing rules.

  3. Async clinical review

    A licensed clinician in your state reviews your history and decides whether the medication is appropriate. Typically within 24-48 hours.

  4. Prescription ships

    If approved, the medication is sent from a partner pharmacy. Initial titration dose arrives in 3-7 days for most US states.

  5. Ongoing support

    Most programs include follow-up check-ins, dose adjustments, and side-effect support. Coverage varies by program.

Sources

Primary references this page draws from. We cite original sources so you can verify any claim.

  1. Clinical trialRetatrutide Phase 2 in obesity (NEJM, 2023)
  2. Clinical trialTRIUMPH Phase 3 retatrutide program (ClinicalTrials.gov)
  3. ManufacturerEli Lilly pipeline media resources

More on Retatrutide

For clinicians: see the Retatrutide prescribing summary.

Share:
We may earn a commission when you click links to partners. Affiliate disclosure.